期刊文献+

瑞舒伐他汀钙合用阿奇霉素引起横纹肌溶解和肝损害1例 被引量:9

原文传递
导出
摘要 目的:研究降脂丸对动脉粥样硬化(AS)大鼠模型炎症因子的影响,探讨其抗动脉粥样硬化的机制。方法:SD大鼠腹腔注射维生素D3后灌胃脂肪乳剂建立动脉粥样硬化模型,并随机分成正常对照组、模型组、降脂丸高、中、低剂量组、辛伐他汀组 ,28 d后用全自动生化仪检测血清C反应蛋白(CRP),HE染色观察主动脉病理学改变,免疫组化法检测主动脉壁细胞间黏附因子-1(IACM-1)。结果:与模型组比较,降脂丸各干预组明显减轻 AS程度,降低血清CRP水平,下调主动脉壁IACM-1表达。结论:降脂丸缓解AS进程效果明显,其机制可能与下调主动脉壁IACM-1的表达有关。
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2013年第20期1736-1737,共2页 Chinese Journal of Hospital Pharmacy
  • 相关文献

参考文献5

二级参考文献6

  • 1任辉.横纹肌溶解症的病理生理、诊断以及治疗[J].国外医学(护理学分册),2005,24(3):112-114. 被引量:6
  • 2邓万俊.他汀类药物与其他药物的相互作用[J].中国新药与临床杂志,2006,25(2):131-136. 被引量:35
  • 3Paul D, Thompson MD, Priscilla M, et al. An Assessment of Statin Safety by Muscle Experts [J]. Am J Cardiol, 2006,97 : 69C-76C.
  • 4Ferdinand KC. The importance of aggressive lipid management in patients at risk: evidence from recent clinical trials[J]. Clin Cardiol,2004,27(6 Suppl 3) : 12-15.
  • 5Thompson PD, Ciarkson P, Karas RH. Statin. associated myopathy[J]. JAMA, 2003,289 ( 13 ) : 1681-1690.
  • 6Kuper JI, D' Aprile M. Drug-drug interations of clinical significance in the treatment of patients with mycobaeterium avium complex disease Ⅲ [J]. Clin Pharmaeokinet, 2000,39 (3) : 203- 214.

共引文献17

同被引文献79

  • 1陈志军.阿托伐他汀结合辅酶Q10治疗冠心病患者的临床疗效分析[J].现代诊断与治疗,2020(7):1071-1073. 被引量:3
  • 2郝伟.我国吸毒现状、相关问题与对策[J].中国药物依赖性杂志,2004,13(3):227-230. 被引量:16
  • 3曲如杰,林霖,王文忠.吸毒者心理健康状况及与复吸原因的关系[J].中国临床心理学杂志,2006,14(1):55-57. 被引量:45
  • 4Giuseppe Famularo,Luca Miele,Giovanni Minisola,Antonio Grieco.Liver toxicity of rosuvastatin therapy[J].World Journal of Gastroenterology,2007,13(8):1286-1288. 被引量:9
  • 5Hanaa A. El Gendy,Noha M. Elsharnouby.Safety and vasopressor effect of rosuvastatin in septic patients[J].Egyptian Journal of Anaesthesia.2014
  • 6Kazuyoshi Kaneko,Hiroki Saito,Tetsuya Takahashi,Nobuyuki Kiribayashi,Koki Ohmi,Toshiki Sasaki,Takeshi Niizeki,Shigeo Sugawara,Masahiro Akasaka,Isao Kubota.Rosuvastatin Improves Plaque Morphology in Cerebral Embolism Patients with Normal Low-Density Lipoprotein and Severe Aortic Arch Plaque[J].Journal of Stroke and Cerebrovascular Diseases.2014
  • 7Rajkiran Mahalwar,Deepa Khanna.Pleiotropic antioxidant potential of rosuvastatin in preventing cardiovascular disorders[J].European Journal of Pharmacology (-).2013(1-3)
  • 8Evan A. Stein,Donald G. Vidt,James Shepherd,Valerie A. Cain,Deborah Anzalone,Michael D. Cressman.Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: A retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program[J].Atherosclerosis.2012(2)
  • 9Judith Hsia,Jean G. MacFadyen,John Monyak,Paul M. Ridker.Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin[J].Journal of the American College of Cardiology.2011(16)
  • 10James Shepherd,Donald B. Hunninghake,Evan A. Stein,John J.P. Kastelein,Susan Harris,John Pears,Howard G. Hutchinson.Safety of rosuvastatin[J].The American Journal of Cardiology.2004(7)

引证文献9

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部